Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: Mar 26, 2020
Date Accepted: Aug 8, 2020

The final, peer-reviewed published version of this preprint can be found here:

Mobile Breast Cancer e-Support Program for Chinese Women With Breast Cancer Undergoing Chemotherapy (Part 3): Secondary Data Analysis

Zhu H, Chen X, Yang J, Wu Q, Zhu J, Chan SWC

Mobile Breast Cancer e-Support Program for Chinese Women With Breast Cancer Undergoing Chemotherapy (Part 3): Secondary Data Analysis

JMIR Mhealth Uhealth 2020;8(9):e18896

DOI: 10.2196/18896

PMID: 32936087

PMCID: 7527913

Mobile Breast Cancer e-Support Program for Chinese Women With Breast Cancer Undergoing Chemotherapy (Part 3): A Secondary Data Analysis

  • Haihua Zhu; 
  • Xiuwan Chen; 
  • Jingqiu Yang; 
  • Qiaoling Wu; 
  • Jiemin Zhu; 
  • Sally Wai-Chi Chan

ABSTRACT

Background:

Women with breast cancer receiving chemotherapy in China face challenges in accessing sufficient and continuous cancer care. Mobile applications (apps) can be a promising tool for delivering support to these women when and where needed. Many app-based interventions have been developed and tested for effectiveness. A better understanding of usage data is important to explain how women use apps and how these interventions affect women’s health outcomes. However, information regarding the evaluation of the usage of these app-based interventions is inadequate.

Objective:

This study aimed to examine the usage duration and login frequency of an app-based intervention, the Breast Cancer e-Support (BCS) program, and to identify the association between usage data and participants’ demographic and medical characteristics.

Methods:

This secondary data analysis focused on a randomized controlled trial assessing the effectiveness of the BCS program. The program contains four modules: Learning Forum, Discussion Forum, Ask-the-Expert Forum, and Your Story Forum. Women in the intervention group accessed the BCS program during their 12-week chemotherapy. The app’s background system tracked the usage duration and login frequency for each forum and the entire BCS program.

Results:

Usage statistics were collected for 12 weeks from 57 women with breast cancer (mean age: 46.2 years). The total usage duration per participant ranged from 0 to 9,371 min, and the login frequency per participant ranged from 0 to 774 times for the 12-week period. The Discussion Forum and Learning Forum were the two highly used modules. The Kruskal–Wallis test showed that education and family income were associated with the usage of the BCS program. Education was positively correlated with usage duration for the 12-week BCS program (χ2 = 15.99, P = .01), Discussion Forum (χ2 = 12.25, P = .02), Ask-the-Expert Forum (χ2 = 10.70, P = .03), and Your Story Forum (χ2 = 9.94, P = .04). Education was also positively correlated with login frequency for Learning Forum (χ2 = 9.71, P = .046), Discussion Forum (χ2 = 12.66, P = .01), and Ask-the-Expert Forum (χ2 = 11.70, P = .02). Family income was positively correlated with usage duration. Family income was also associated with usage duration for the BCS program (χ2 = 8.09, P = .04) and Your Story Forum (χ2 = 14.75, P = .01). No statistical difference was found between usage of the BCS program and age, BMI, cancer stage, employment, comorbidity, or type of surgery.

Conclusions:

Overall, this study illustrated the individualized and diverse usage of app-based programs. The learning and discussion functions of the app need to be strengthened to promote participants’ engagement. The insights gained from this study could provide recommendations for further advances in the design of app-based programs. In developing tailored app-based programs that will engage women with diverse needs, the needs of women with different levels of education and income should be explored. Clinical Trial: ACTRN: ACTRN12616000639426, Registered May 17, 2016. http://www.ANZCTR.org.au/ACTRN12616000639426.aspx.


 Citation

Please cite as:

Zhu H, Chen X, Yang J, Wu Q, Zhu J, Chan SWC

Mobile Breast Cancer e-Support Program for Chinese Women With Breast Cancer Undergoing Chemotherapy (Part 3): Secondary Data Analysis

JMIR Mhealth Uhealth 2020;8(9):e18896

DOI: 10.2196/18896

PMID: 32936087

PMCID: 7527913

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.